ImmunityBio
IBRX
62 hedge funds and large institutions have $124M invested in ImmunityBio in 2016 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 32 increasing their positions, 10 reducing their positions, and 8 closing their positions.
220% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 10
60% more call options, than puts
Call options by funds: $599K | Put options by funds: $374K
0% more funds holding
Funds holding: 62 → 62 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
28% less capital invested
Capital invested by funds: $172M → $124M (-$48.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.76M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$627K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$445K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIM
RS Investment Management
San Francisco,
California
|
-$9.15M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$5.58M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$1.51M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
-$951K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$539K |
IBRX Hedge Fund Activity: Q2 2016 in Review
62 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ImmunityBio (IBRX) for Q2 2016, worth a combined $124M — down 28% from $172M a quarter earlier.
Fund positioning in IBRX was balanced in Q2 2016: 8 funds opened new positions, 8 closed out, 32 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $1.76M. The largest seller was RS Investment Management, exiting entirely with an estimated $9.15M sold.
- 62 institutional investors held ImmunityBio (IBRX) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $124M of ImmunityBio stock for Q2 2016, down 28% quarter-over-quarter.
- 8 funds opened new ImmunityBio positions in Q2 2016 and 8 closed out, a net change of 0 holders.
- The largest ImmunityBio buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $1.76M added.
- The largest ImmunityBio seller in Q2 2016 was RS Investment Management, an estimated $9.15M sold.
Based on aggregated 13F filings for Q2 2016.